<SEC-DOCUMENT>0000950142-23-001375.txt : 20230508
<SEC-HEADER>0000950142-23-001375.hdr.sgml : 20230508
<ACCEPTANCE-DATETIME>20230508061407
ACCESSION NUMBER:		0000950142-23-001375
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230508
DATE AS OF CHANGE:		20230508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		23895776

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>eh230356796_defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SCHEDULE 14A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Proxy Statement Pursuant to Section 14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Amendment No.&nbsp; )</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Filed by the Registrant&nbsp; <FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Filed by a Party other than the Registrant&nbsp; <FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-size: 10pt">Preliminary Proxy Statement</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Definitive Proxy Statement</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Definitive Additional Materials</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Soliciting Material Pursuant to &sect;240.14a-12</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; width: 100%; text-align: center"><FONT STYLE="font-size: 12pt"><B>EXELIXIS, INC. </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Name of Registrant as Specified In Its Charter)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Payment of Filing Fee (Check all boxes that apply):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9746;</FONT></TD>
    <TD STYLE="width: 95%">No fee required</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></TD>
    <TD>Fee paid previously with preliminary materials</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></TD>
    <TD>Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; ">On
May 1, 2023, Exelixis, Inc. issued the following press release.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 8pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 50%"><IMG SRC="logo.jpg" ALT="">&nbsp;</TD>
    <TD STYLE="width: 50%">
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: right"><B><I>Investor Contacts:</I></B></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: right"><I>Chris Senner</I></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: right"><I>Chief Financial Officer</I></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: right"><I>Exelixis, Inc.</I></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: right"><I>650-837-7240</I></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: right"><FONT STYLE="color: #0563C1"><I><U>csenner@exelixis.com</U></I></FONT></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: right"><I>&nbsp;</I></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: right"><I>Susan Hubbard</I></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: right"><I>EVP, Public Affairs &amp; Investor Relations</I></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: right"><I>Exelixis, Inc.</I></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: right"><I>650-837-8194</I></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: right"><FONT STYLE="color: #0563C1"><I><U>shubbard@exelixis.com</U></I></FONT></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: right"><I>&nbsp;</I></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: right"><B><I>Media Contacts:</I></B></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: right"><I>Jamie Moser / Sharon Stern / Tali Epstein<BR>
    Joele Frank, Wilkinson Brimmer Katcher<BR>
    212-355-4449</I></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>


<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>EXELIXIS ANNOUNCES DEPARTURE OF LANCE WILLSEY, M.D.
FROM BOARD OF DIRECTORS </B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>ALAMEDA, Calif. &ndash; May 7, 2023 </B>&ndash;&nbsp;<FONT STYLE="color: #0563C1"><U>Exelixis,
Inc.</U></FONT> (Nasdaq: EXEL) (the &ldquo;Company&rdquo;) today announced that Lance Willsey, M.D. has informed the Board of Directors
of his decision to resign from the Board, effective immediately. The Board recommends shareholders vote in favor of its remaining 10
director nominees and will not contest the election of Farallon Capital Management&rsquo;s (&ldquo;Farallon&rdquo;) additional nominee,
David Johnson, at the upcoming 2023 Annual Meeting of Shareholders, to be held on May 31, 2023.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">As previously announced, the Board nominated two of Farallon&rsquo;s originally
proposed candidates &ndash; Tomas Heyman and Robert Oliver &ndash; to replace two of its existing directors at the Annual Meeting. The
Board is actively identifying, evaluating and interviewing candidates as part of its continued refreshment program, which includes a commitment
to replacing two additional directors, one in each of the next two years, with two new independent directors. Following the upcoming Annual
Meeting, five directors will have transitioned off the Board in the past three years, and four new independent directors will have been
elected, including all of Farallon&rsquo;s nominees.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">The Board supports Dr. Willsey&rsquo;s decision, which will end the need
for Farallon to continue its proxy campaign. The Company is focused on advancing its mission to develop life-changing cancer therapies
and build long-term shareholder value. Dr. Willsey&rsquo;s decision to resign is in connection with a personal matter that occurred more
than a decade ago. The Company engaged outside legal counsel at that time to review the matter and the Board at the time decided that
no action was needed with respect to Dr. Willsey&rsquo;s Board representation.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; "><B><U>About&nbsp;Exelixis</U></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; ">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; ">Exelixis&nbsp;is a globally ambitious oncology
company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by bi-coastal centers of discovery
and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications
with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive
approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the
impact of our flagship commercial product, CABOMETYX<SUP>&reg;</SUP>&nbsp;(cabozantinib).&nbsp;Exelixis&nbsp;is driven by a bold scientific
pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission
to help cancer patients recover stronger and live longer, visit&nbsp;www.exelixis.com, follow&nbsp;@ExelixisInc&nbsp;on Twitter, like&nbsp;Exelixis,
Inc.&nbsp;on Facebook and follow&nbsp;Exelixis&nbsp;on LinkedIn.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B><U>Exelixis Forward-Looking Statements</U></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">This document contains forward-looking statements. Any statements that refer
to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based
upon Exelixis&rsquo; current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve
risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking
statements as a result of these risks and uncertainties, which include, without limitation the factors affecting Exelixis discussed under
the caption &ldquo;Risk Factors&rdquo; in Exelixis&rsquo; Annual Report on Form 10-K filed with the SEC on February 7, 2023, and in Exelixis&rsquo;
future filings with the SEC. All forward-looking statements in this document are</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>






<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">based on information available to Exelixis as of the date of this document,
and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B><U>Important Information Regarding the GOLD Proxy Card</U></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Exelixis does not intend to circulate an updated GOLD proxy card as a result
of Dr. Lance Willsey&rsquo;s resignation from the Board of Directors.&nbsp;The persons named as proxies in the GOLD proxy card will vote
the relevant shares of Exelixis common stock at the 2023 Annual Meeting as indicated on such proxy card with respect to each of the remaining
nominees recommended by the Exelixis Board of Directors (the &ldquo;Board Recommended Nominees&rdquo;).&nbsp;However, no votes will be
cast for Dr.&nbsp;Willsey.&nbsp;If any GOLD proxy card is submitted with no voting instructions, the relevant shares will be voted &ldquo;FOR&rdquo;
each of the remaining Board Recommended Nominees and no votes will be cast for Dr.&nbsp;Willsey.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B><U>Important Stockholder Information</U></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Exelixis has filed a definitive proxy statement, containing a form of GOLD
proxy card, with the SEC in connection with its solicitation of proxies for its 2023 Annual Meeting. THE COMPANY&rsquo;S SHAREHOLDERS
ARE STRONGLY ENCOURAGED TO READ THE DEFINITIVE PROXY STATEMENT (AND ANY AMENDMENTS AND SUPPLEMENTS THERETO) AND ACCOMPANYING GOLD PROXY
CARD AS THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. Shareholders may obtain a copy of the definitive proxy statement, any amendments
or supplements to the proxy statement and other documents filed by the Company with the SEC without charge from the SEC&rsquo;s website
at&nbsp;<FONT STYLE="color: #0563C1"><U>www.sec.gov</U></FONT>.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">The Company, its Directors and certain of its executive officers may be
deemed to be participants in connection with the solicitation of proxies from the Company&rsquo;s shareholders in connection with the
matters to be considered at the 2023 Annual Meeting. Information regarding the ownership of the Company&rsquo;s Directors and executive
officers in the definitive proxy statement for its 2023 Annual Meeting, filed with the SEC on May 1, 2023, can be found through the SEC&rsquo;s
website at&nbsp;<FONT STYLE="color: #0563C1"><U>www.sec.gov</U></FONT>. Changes to such ownership have been or will be reflected on Statements
of Changes in Beneficial Ownership on Form 4 filed with the SEC. Details concerning the nominees of the Exelixis&rsquo; Board of Directors
for election at the 2023 Annual Meeting are also included in such definitive proxy statement. These documents can be obtained free of
charge from the sources indicated above.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><I>Exelixis, the Exelixis logo, and CABOMETYX are registered
trademarks of Exelixis, Inc.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><I>###</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>




<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !  +\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V:BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HI*R/$>N#0K!95C$DLC;8U)P,]234S
MFH1<I;(NG3E5FH06K-BBN4\,^+I=7O39W<,:2E2R/'G!QU!!K>U34H-*L7N;
M@G"\*HZNW8#WJ*=>%2'/%Z&E7#5:53V4EJ7:*IZ8MR+-7OFS<2'>RCHF>BCZ
M"KE:)W5S%JSL%%%%,04444 %<+K_ (]O-,UJXLK6U@9(2%+29RQP#V/O7=5Y
M%X@E6#QU<S29V1W2.V!V&TFF@-/_ (61JO\ SXVW_?+_ .-='X2\1ZAK[7)N
MK6.&*-1L=%;!8YXY--_X6#H7K/\ ]^36SH^LVFMVK7%EO,:.4.]=O. ?ZT <
MK>^-]4T;6C9ZI96_E*W+1;@60_Q+D_I^%=K!<Q7-LEQ#(KPR+N5P>"*R/%/A
MV/7].*KA;N+YH7/K_=/L:\UCUO4M,TNZT?<T2,Y#J?O1_P!Y1['O_P#7H ZR
M^\?74FM?8M%M8;E"PC1GSEV[D8/3_P#76]K^M7.@^'UNY(XI;HE4*C(3<>OO
MC@UF^"/"_P#9=L+^\3%Y,ORJ?^62GM]3W_*G_$;_ )%E?^OA/Y&@# 'Q)U4]
M+*U/T#_XT^+XAZS/,D4>G6[.Y "JCDG]:/!_BK3=$T=[:],OFF9G&V/<,$#_
M  KI++QOH]]>PVL!F\V9@B9BP,GWH$7O$>KOHFB2WL<2R2*5558X&2<<U!X3
MUN?7]*>ZN8XXW68QXCSC  /?ZU6^('_(IS?]=(__ $(57^&W_(N2_P#7RW_H
M*T#.MKB[GQO=)XL&EPVT/D"X6 NV2QR0"?3O7:5Y-<_\E'/_ &$5_P#0A0@.
MW\4:SJ.B"*:VAADMG^5BX.5;MT/0U7MY+;QSHACN/W%U"^3LYVGL1[$5T5]9
M1:A92VLXS'(N#[>]>:6<]SX3\1%902(VV2@?QH>X_G7FXF4J51.>L):/R/7P
M5.->BU3TJQU3[G7:-X:M?#9EO[JZ\QD0_.1M5%[_ (U2TN63Q7X@-_,I&GV1
M_<QGH6[$^_?\JS/$VOR:]>1Z?IQ+6Y< 8X\UC_05V^CZ9'I.F0VD?.P99O[S
M'J:*2C4G[.G\$?Q85W.E3]K6=ZD]O)?\$YKQ1XUN=$U;[%:VT+A4#,TF>2?3
M%=5=WL-C827=T^R*--[&O,/'_P#R-LW_ %RC_E7=>+K*>_\ "EQ%;(7D 1P@
MZL 03BO2/(.6NOB)J=U.PTRR18QT#(9&Q[XZ4MG\2+VWFV:I9HR@_-L!1Q^!
MK,\+>+/^$=6:)[031RMN+*=K@XQ^-=C9^*?#VN7$0G2-+@$;!<Q#.?9NE B]
MJ.KS11V[VZ[4E0/EUY /J#TQW^M:EI,;BUCE8 %USQT_#VI\D4<H D17 .1N
M&:=2&+7D7B"-)O'5S'+_ *M[I%;G'!V@\UZ[7#ZSX N=4UBZO4OHHUF?<%,9
M)' 'K[4T!=_X0WPS[?\ @2?\:W=*M+#3[46NG>6L2\E5;<<GN:X?_A6%U_T$
M(/\ OT?\:Z#PKX3?PXUS*]RLTLP"@*NU0!S_ %H E\7>)5T&PV0D&]G!$2_W
M1W8_3^=>?VWAG4=2T6XU=07 ;<%/+RC^)A_GGFNJN/ =WJ>LF]U348Y5=\R(
MB$':.BCG@=J[2*)(8DCC4(B *JCH .U ''>!?%'VV%=,O7S<1K^Y<G_6*.WU
M'ZBK/Q&_Y%E?^OA/Y&JVJ> #-JQO=+O%M"6\S:5)V/ZKCM[5KZ]H=UKN@Q64
MMQ$EPKJ[R!#M8@'.!^- '*>$/#^CZKH[SZCCSA,RC]]M^4 8XS[FNGT[P[X?
MTN[6ZMO+\Y/NL\V[;[C)KFO^%871_P"8A!_WZ/\ C3HOAA,)D,NH1>6&&[;$
M<X]N:!&_\0/^13F_ZZ1_^A"J?PZN(8O#LJR2QH?M+'#,!V6MOQ'H[ZWHSV44
MJQ,S*=S#(X.:X_\ X5A='_F(0?\ ?H_XT#/04N8)&"I-&S'LK FO*[G_ )*.
M?^PBO_H0KJ?#7@5]$U9;Z>[24QJ0BHF.2,9/X4O_  @\C^*FU66\7ROM'GB-
M4.[CD#- '3WMY%86<MS.<1Q*6->?Z-ID_BO6IKZ\R+8/ND/KZ(/PK;\1M/KV
MK1:)9L1''B2ZD'1?0?\ UO7%=+8V4.GVD=M;)MBC& /7W/O7#.'UBI9_#'\7
M_P  ]*E5^J46X_'+\%_FSSWQ9HS:)J:75F#'!*VZ,K_RS<=OZBNU\/:PNM:6
MD_ F7Y)5'9O\#UJSJNFPZMI\MI/PKCAAU4]B*PO#_A>]T+4#,+V*2%QMDC"D
M;AV/UJ849T:]X+W9;^1=3$4\3A5&H[3CMYHY#Q__ ,C;-_URC_E7I]Q>6]A8
M_:+N98H4 R['BN9U[P1)KFNF]-XD4+!%9-A+8'7!KH-5T>UUFP-I>(3'D%2I
MP5(Z$5Z!Y1EMIWAKQ.K3QK;S.>KQ-L?\<8/YUQ/C#P_9:%<0+9W+2"7.Z)R"
MR8QSGT.:U+GX9W:2DV=_$R=O,4JP_*IM/^&C^>'U.\5HP>4A!RWL6/2@1T_A
M.>:X\+V$EP29#'C)ZD D _D!6Q3(HD@A2*)0D: *JCH .@I](84444 %%%%
M!1110 4444 %%%% !1110 5#=/*EM(UNGF2@?(I. 3VS[5-10P1GZ1I::9;,
MI;S+B5O,GE/61SU/T]*T***48J*LBI2<GS,****9(4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
